Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo.
Nathan W. Cummins, Jason Baker, Rana Chakraborty, Patrick G. Dean, Enrique Garcia-Rivera, Ashton Krogman, Shaji Kumar, Yury V. Kuzmichev, Gregory M. Laird, Alan Landay, Mathias Lichterfeld, Maryam Mahmood, Jeffrey Martinson, Mark Maynes, Sekar Natesampillai, Vincent Rajkumar, Yelizaveta Rassadkina, Kristen D. Ritter, Christina G. Rivera, Stacey A. RizzaKrupa Subramanian, Aaron J. Tande, Elizabeth R. Wonderlich, Jennifer A. Whitaker, John Zeuli, Andrew D. Badley
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo.'. Together they form a unique fingerprint.